4/6
09:23 am
trda
Entrada Therapeutics (TRDA) had its price target raised by Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have an "outperform" rating on the stock.
Medium
Report
Entrada Therapeutics (TRDA) had its price target raised by Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have an "outperform" rating on the stock.
4/1
09:00 am
trda
Entrada Therapeutics (TRDA) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Entrada Therapeutics (TRDA) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/28
01:05 am
trda
Low
Report
3/2
04:30 pm
trda
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
01:30 am
trda
Low
Report
2/26
07:32 am
trda
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
07:00 am
trda
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2/18
08:13 am
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/17
07:30 am
trda
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study [Yahoo! Finance]
Low
Report
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study [Yahoo! Finance]
2/17
07:00 am
trda
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Low
Report
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
2/13
06:29 am
trda
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
High
Report
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/10
06:05 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) was given a new $20.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) was given a new $20.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
2/4
08:29 am
trda
Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/4
07:00 am
trda
Entrada Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Entrada Therapeutics to Present at Upcoming Investor Conferences
1/28
08:00 am
trda
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.